The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:2092-2093 November 15, 2007 Number 20
NextNext

Multiple Alloantibodies after Transfusion in an Infant Treated with Infliximab

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Infliximab (Remicade) is a humanized mouse monoclonal antibody that blocks tumor necrosis factor {alpha}.1 It down-regulates type 1 helper T-cell (Th1) immune responses and increases type 2 helper T-cell (Th2) responses, thereby favoring antibody production.2 There are many reports of autoantibody formation after the administration of infliximab, including a case of autoimmune hemolytic anemia.1 We report on a 10-month-old boy who received infliximab for systemic-onset juvenile rheumatoid arthritis and who had a severe hemolytic transfusion reaction.

At the time of his initial admission, the patient's hemoglobin level was 8.3 g per deciliter, and his hematocrit was 19.2%. . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.